OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Immunology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)	209
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset	174
Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients	99
Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID‐19 patients with pneumonia	93
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments	87
Human NK cells, their receptors and function	82
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action	76
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy	70
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans	67
MDSC subtypes and CD39 expression on CD8⁺ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC	58
Prevention and treatment of COVID‐19 disease by controlled modulation of innate immunity	56
Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway	56
Highly multiplexed tissue imaging using repeated oligonucleotide exchange reaction	53
Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA‐DR15	52
Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patients	50
JAK inhibitors: Ten years after	50
The expanding world of tissue‐resident macrophages	50
High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris	49
TNF‐α and IL‐1β sensitize human MSC for IFN‐γ signaling and enhance neutrophil recruitment	48
CD8⁺ Tregs revisited: A heterogeneous population with different phenotypes and properties	47
Treg cell therapy: How cell heterogeneity can make the difference	47
Transcriptional and posttranslational regulation of Th17/Treg balance in health and disease	43
Complement cascade in severe forms of COVID‐19: Recent advances in therapy	43
CAR T cells: Building on the CD19 paradigm	42
Peptide microarray‐based analysis of antibody responses to SARS‐CoV‐2 identifies unique epitopes with potential for diagnostic test development	41

Immune response in children with COVID‐19 is characterized by lower levels of T‐cell activation than infected adults	40
Tc17 biology and function: Novel concepts	40
Helios is a marker, not a driver, of human Treg stability	39
Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients	38
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8⁺ T cells	38
Metabolic reprograming shapes neutrophil functions in severe COVID‐19	35
Comprehensive characterization of myeloid cells during wound healing in healthy and healing‐impaired diabetic mice	35
Differential Interleukin‐8 thresholds for chemotaxis and netosis in human neutrophils	33